18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

Naghmehossadat Eshghi*, Tamara F. Lundeen, Lea Mackinnon, Ryan Avery, Phillip H. Kuo

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Scopus citations


An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

Original languageEnglish (US)
Pages (from-to)e142-e144
JournalClinical nuclear medicine
Issue number5
StatePublished - May 1 2018



  • Merkel cell carcinoma
  • avelumab
  • immunotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this